Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.
Joined June 2018
- Tweets2K
- Following1.2K
- Followers1.1K
- Likes6K
Evan Hall retweeted
Fantastic @StanfordDeptMed Grand Rounds now for the memorial @BGabster lecture
@DianaCejasMD presents on writing and illness. & some basic neuroanatomy for us internists
A special gathering for our community. Our gratitude to Dr. Gabster’s family.
medicine.stanford.edu/news/c…
Evan Hall retweeted
The Phase 2/3 Randomized trial of RP2+nivolumab for #uveal #melanoma is now OPEN at @StanfordCancer. This is for patients who have not had prior checkpoint inhibitors or liver-directed therapy. Prior tebentafusp is allowed. The phase 1 data were quite promising and we're excited to be able to offer this to our patients!
Evan Hall retweeted
Representing @fredhutch @UWMedicine @uwsomwwami Kidney Cancer Multidisciplinary Team #IKCSNA2024 @KidneyCancer @spsutkaMD
Evan Hall retweeted
Nice to see this out there! Dr. Silk did a heroic job leading this trial of tvec and nivolumab in rare skin cancers. A collaboration that has spanned many institutions! @Perlmutter_CC @DanaFarber @theNCI @RutgersCancer
Evan Hall retweeted
Fantastic work @LisaTachiki @BhatiaS_MD @fredhutch et al.
@FredHutchGO @HutchPresident @nicoleflemingmd @JessicaHawleyMD @RahulBanerjeeMD @EvanHallMD @btfoundation @binayshah @MonikaJoshimd @UWMedicine @AJPortuguese @HannahRAbrams @natashakwemd @valdesan @OncoAlert @sitcancer
This Post is from an account that no longer exists. Learn more
Evan Hall retweeted
New #JITC article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses bit.ly/4dIbUHP @BhatiaS_MD @PaulNghiem
@DrBetofMDPhD @StanfordCancer presents on TIL for patients with untreated brain metastases post PD-1 at #SMR24. Very important area to generate data. Time for TIL process, need for anesthesia/harvest, chemotherapy causing ⬇️plts, IL-2 etc complicate this scenario. 1/
Evan Hall retweeted
Very proud to be part of multidisciplinary kidney cancer clinic @fredhutch providing 1 stop service for kidney cancer patients@spsutkaMD @DanLinMD @schadegr @EvanHallMD @LisaTachiki @WinstonVuong @MartinMaMDPhD
Evan Hall retweeted
Find yourself doctors (and colleagues) that get excited about moving the field forward like @alexshoushtari and @DrBetofMDPhD
Reunion of kindred spirits this morning at Living with Melanoma @AIMatMelanoma and @StanfordCancer
Evan Hall retweeted
Are you interested in how to select side-effects for ePRO symptom monitoring ?
We conducted a national modified Delphi to do just that for #immunotherapy side-effects in routine care and found limited coverage of clinically relevant side-effects by existing PROMs @JCOOP_ASCO
Evan Hall retweeted
Excited to present @ASCO highlights in GU cancers in @ScrippsHealth in Seattle! So much great data to cover! @fredhutch @shilpaonc @Uromigos @urotoday @OncoAlert @valdesan @EvanHallMD @BhatiaS_MD @JessicaHawleyMD @RahulBanerjeeMD @montypal @neerajaiims @jrgralow @TiansterZhang
Evan Hall retweeted
That Seattle 5k was fantastic! 🤩
We had 122 people race for a cure with us! Thank you to each and every one of you! We are so appreciative of all of your support! 🥇
We were able to raise over $10,000! 👏 👏 👏
And we'd like to thank @fredhutch for sponsoring this event!
Evan Hall retweeted
Check out our latest paper on the development of the new @EORTC_QLG advanced #melanoma module.
Great to contribute 🇦🇺 perspectives from @MelanomaAus. @PeterMacCC patients will also be included in Phase 3. #melsm
authors.elsevier.com/c/1jFvH…
Evan Hall retweeted
As the sun sets on #asco24 I’d be remiss not to say that I’m worried about my colleagues
I worry we are crushing one another with colossal expectations, with our emails & CVs
You are more than your publications & presentations
Please don’t tie your self-worth to brass rings
Evan Hall retweeted
#irAE outcomes needs to be right next to Progression free survival and Disease free survival as a core outcome.
Thank you @jillfeldman4 @thenasheffect @EladSharonMD @FunchainMD for amplifying this message.
#ASCO24
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
#ASCO24
Evan Hall retweeted
Right on @jillfeldman4 ! Understanding and mitigating irAEs especially the long term ones that affect quality of life for many people post IO needs to be a high priority area!
@DrJNaidoo @EladSharonMD @FunchainMD @kreynoldsMD @ACortelliniMD @BiagioRicciutMD @afreenshariffmd
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
#ASCO24
Evan Hall retweeted
#irAE Outcomes should be reported right next to progression free survival and disease-free survival outcomes.
Thank you @jillfeldman4 @thenasheffect @EladSharonMD @FunchainMD @EvanHallMD @ASCOPost for amplifying this message.
#ASCO24
Right on @jillfeldman4 ! Understanding and mitigating irAEs especially the long term ones that affect quality of life for many people post IO needs to be a high priority area!
@DrJNaidoo @EladSharonMD @FunchainMD @kreynoldsMD @ACortelliniMD @BiagioRicciutMD @afreenshariffmd